litlas
Log inCreate account

Mark B. Pepys

Active 1975–2025

128
Papers
44,486
Citations
97
h-index
127
i10-index

Citations

Citations per year for Mark B. Pepys1964: 1 citations1976: 3 citations1977: 2 citations1978: 3 citations1979: 11 citations1980: 17 citations1981: 26 citations1982: 49 citations1983: 35 citations1984: 28 citations1985: 32 citations1986: 31 citations1987: 38 citations1988: 50 citations1989: 21 citations1990: 57 citations1991: 45 citations1992: 45 citations1993: 42 citations1994: 116 citations1995: 91 citations1996: 101 citations1997: 205 citations1998: 176 citations1999: 264 citations2000: 356 citations2001: 409 citations2002: 420 citations2003: 519 citations2004: 578 citations2005: 651 citations2006: 580 citations2007: 464 citations2008: 459 citations2009: 415 citations2010: 420 citations2011: 417 citations2012: 349 citations2013: 366 citations2014: 300 citations2015: 286 citations2016: 236 citations2017: 219 citations2018: 240 citations2019: 775 citations2020: 782 citations2021: 628 citations2022: 477 citations2023: 307 citations2024: 460 citations2025: 199 citations2026: 3 citations1965–1975: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,272 citing papers, 26% of this breakdownUnited Kingdom: 1,497 citing papers, 11.9% of this breakdownItaly: 750 citing papers, 6% of this breakdownGermany: 711 citing papers, 5.7% of this breakdownChina: 644 citing papers, 5.1% of this breakdownJapan: 428 citing papers, 3.4% of this breakdownFrance: 390 citing papers, 3.1% of this breakdownNetherlands: 387 citing papers, 3.1% of this breakdownCanada: 365 citing papers, 2.9% of this breakdownAustralia: 340 citing papers, 2.7% of this breakdownSweden: 326 citing papers, 2.6% of this breakdownSpain: 268 citing papers, 2.1% of this breakdown
0%26%Other 25.4%

Institutions

Fields

  • Medicine54.2%
  • Biochemistry, Genetics and Molecular Biology26%
  • Immunology and Microbiology8.1%
  • Neuroscience3%
  • Materials Science1.4%
  • Nursing1%
  • Other6.3%

Topics

  • Adipokines, Inflammation, and Metabolic Diseases6.3%
  • Amyloidosis: Diagnosis, Treatment, Outcomes4.2%
  • Alzheimer's disease research and treatments4.2%
  • Inflammatory Biomarkers in Disease Prognosis2.2%
  • Protein Structure and Dynamics2.2%
  • Atherosclerosis and Cardiovascular Diseases1.9%
  • Other79%

Coauthors

All papers

Open in search
  1. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

    Authors: Stephen Kaptoge, Stephen Kaptoge, Emanuele Di Angelantonio, Gordon Lowe, Mark B. Pepys, Simon G. Thompson, Rory Collins - The Lancet 2009 cited by 2,503

  2. C-reactive protein: a critical update

    Authors: Mark B. Pepys, Gideon M. Hirschfield - Journal of Clinical Investigation 2003 cited by 3,513

  3. C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease

    Authors: John Danesh, Jeremy G. Wheeler, Gideon M. Hirschfield, Shinichi Eda, Guðný Eiríksdóttir, Ann Rumley, Gordon Lowe, Mark B. Pepys, Vilmundur Guðnason - New England Journal of Medicine 2004 cited by 2,954

  4. Common core structure of amyloid fibrils by synchrotron X-ray diffraction 1 1Edited by F. E. Cohen

    Authors: Margaret Sunde, Louise C. Serpell, Mark Bartlam, Paul E. Fraser, Mark B. Pepys, Colin Blake - Journal of Molecular Biology 1997 cited by 1,706

  5. The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

    Authors: Giovanna Liuzzo, Luigi M. Biasucci, J. Ruth Gallimore, Rita L. Grillo, Antonio G. Rebuzzi, Mark B. Pepys, Attilio Maseri - New England Journal of Medicine 1994 cited by 2,353

  6. The physiological structure of human C-reactive protein and its complex with phosphocholine

    Authors: Darren A. Thompson, Mark B. Pepys, Steve Wood - Structure 1999 cited by 827

  7. Targeting C-reactive protein for the treatment of cardiovascular disease

    Authors: Mark B. Pepys, Gideon M. Hirschfield, Glenys A. Tennent, J. Ruth Gallimore, Melvyn Kahan, Vittorio Bellotti, Philip N. Hawkins, R. M. Myers, Martin D. Smith, Alessandra Polara, Alexander J. A. Cobb, Steven V. Ley, J. Andrew Aquilina, Carol V. Robinson, Isam Sharif, Gillian A. Gray, Caroline Sabin, Michelle C. Jenvey, Simon Kolstoe, Darren A. Thompson, Stephen P. Wood - Nature 2006 cited by 676

  8. A novel mechano‐enzymatic cleavage mechanism underlies transthyretin amyloidogenesis

    Authors: Julien Marcoux, P. Patrizia Mangione, Riccardo Porcari, Matteo T. Degiacomi, Guglielmo Verona, Graham W. Taylor, Sofia Giorgetti, Sara Raimondi, Sarah Cianférani, Justin L. P. Benesch, Ciro Cecconi, Mohsin M. Naqvi, Julian D. Gillmore, Philip N. Hawkins, Monica Stoppini, Carol V. Robinson, Mark B. Pepys, Vittorio Bellotti - EMBO Molecular Medicine 2015 cited by 164

  9. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

    Authors: Duncan Richards, Louise Cookson, Aliénor Berges, Sharon V. Barton, Thirusha Lane, James M. Ritter, Marianna Fontana, James Moon, Massimo Pinzani, Julian D. Gillmore, Philip N. Hawkins, Mark B. Pepys - New England Journal of Medicine 2015 cited by 376

  10. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis

    Authors: Duncan Richards, Louise Cookson, Sharon V. Barton, Lia Liefaard, Thirusha Lane, David F. Hutt, James M. Ritter, Marianna Fontana, James Moon, Julian D. Gillmore, Ashutosh Wechalekar, Philip N. Hawkins, Mark B. Pepys - Science Translational Medicine 2018 cited by 137

  11. C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men

    Authors: Wolfgang Köenig, M. Sund, Margit Fröhlich, Hans-Günther Fischer, Hannelore Löwel, Angela Döring, Winston L. Hutchinson, Mark B. Pepys - Circulation 1999 cited by 1,947

  12. Three dimensional structure of human C-reactive protein

    Authors: A.K. Shrive, Graham M.T. Gheetham, David W. Holden, Dean A. A. Myles, William G. Turnell, John E. Volanakis, Mark B. Pepys, Anne C. Bloomer, Trevor J. Greenhough - Nature Structural & Molecular Biology 1996 cited by 364

  13. Serum levels of C‐reactive protein in Crohn's disease and ulcerative colitis

    Authors: Evelyn Fagan, Roland Dyck, Paul N. Maton, H. J. F. Hodgson, V. S. Chadwick, Aviva Petrie, Mark B. Pepys - European Journal of Clinical Investigation 1982 cited by 313

  14. Plasminogen activation triggers transthyretin amyloidogenesis in vitro

    Authors: P. Patrizia Mangione, Guglielmo Verona, Alessandra Corazza, Julien Marcoux, Diana Canetti, Sofia Giorgetti, Sara Raimondi, Monica Stoppini, Marilena Esposito, Annalisa Relini, Claudio Canale, Maurizia Valli, Loredana Marchese, Giulia Faravelli, Laura Obici, Philip N. Hawkins, Graham W. Taylor, Julian D. Gillmore, Mark B. Pepys, Vittorio Bellotti - Journal of Biological Chemistry 2018 cited by 106

  15. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis

    Authors: David R. Booth, Margaret Sunde, Vittorio Bellotti, Carol V. Robinson, Winston L. Hutchinson, Paul E. Fraser, Philip N. Hawkins, Christopher M. Dobson, Sheena E. Radford, Colin Blake, Mark B. Pepys - Nature 1997 cited by 1,048

  16. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.

    Authors: David M. Vigushin, Mark B. Pepys, Philip N. Hawkins - Journal of Clinical Investigation 1993 cited by 642

  17. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein

    Authors: Julian D. Gillmore, Laurence Lovat, M.R. Persey, Mark B. Pepys, Philip N. Hawkins - The Lancet 2001 cited by 601

  18. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis

    Authors: P. Patrizia Mangione, Riccardo Porcari, Julian D. Gillmore, Piero Pucci, Maria Monti, Mattia Porcari, Sofia Giorgetti, Loredana Marchese, Sara Raimondi, Louise C. Serpell, Wenjie Chen, Annalisa Relini, Julien Marcoux, Innes Clatworthy, Graham W. Taylor, Glenys A. Tennent, Carol V. Robinson, Philip N. Hawkins, Monica Stoppini, Stephen P. Wood, Mark B. Pepys, Vittorio Bellotti - National Academy of Sciences, Proceedings of the National Academy of Sciences 2014 cited by 125

  19. Amyloidosis

    Authors: Mark B. Pepys - Annual Review of Medicine 2005 cited by 553

  20. Low‐level increases in serum C‐reactive protein are present in early osteoarthritis of the knee and predict progressive disease

    Authors: Tim D. Spector, Deborah Hart, D. Nandra, David Doyle, N. Mackillop, J. Ruth Gallimore, Mark B. Pepys - Arthritis & Rheumatism 1997 cited by 402

  21. Solid phase radioimmunoassays for human C-reactive protein

    Authors: Brian Shine, Frits C. de Beer, Mark B. Pepys - Clinica Chimica Acta 1981 cited by 319

  22. Human plasma fibrinogen is synthesized in the liver

    Authors: Glenys A. Tennent, Stephen O. Brennan, Arie J. Stangou, John O’Grady, Philip N. Hawkins, Mark B. Pepys - Blood 2006 cited by 315

  23. Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis

    Authors: Ivana Slámová, Rozita Adib, Stéphan Ellmerich, Michal R. Golos, Janet A. Gilbertson, Nicola Botcher, Diana Canetti, Graham W. Taylor, Nigel B. Rendell, Glenys A. Tennent, Guglielmo Verona, Riccardo Porcari, P. Patrizia Mangione, Julian D. Gillmore, Mark B. Pepys, Vittorio Bellotti, Philip N. Hawkins, Raya Al‐Shawi, J. Paul Simons - Nature Communications 2021 cited by 37

  24. Human lysozyme gene mutations cause hereditary systemic amyloidosis

    Authors: Mark B. Pepys, Philip N. Hawkins, David R. Booth, David M. Vigushin, GA Tennent, Anne K. Soutar, Nicholas F. Totty, Ong Nam Phuong Nguyen, C. C. F. Blake, C. J. Terry, Terry Feest, A. M. Zalin, J. Justin Hsuan - Nature 1993 cited by 662